Inhibition of Selenoprotein I promotes ferroptosis and reverses resistance to platinum chemotherapy by impairing Akt phosphorylation in ovarian cancer
MedComm · 2024-12 · 5 (12)
DOI: 10.1002/mco2.70033 ↗Kurz gefasst
Fachartikel in der Zeitschrift MedComm, online erschienen am 11.12.2024. Verfasst von Jing Li und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gynecology Shenzhen Second People's Hospital the First Affiliated Hospital of Shenzhen University Shenzhen China. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 82 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Key Research and Development Program of China, National Natural Science Foundation of China.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Ovarian cancer (OV) ranks among the deadliest gynecological cancer, known for its high risk of relapse and metastasis, and a general resistance to conventional platinum‐based chemotherapy. Selenoprotein I (SELENOI) is a crucial mediator implicated in human hereditary spastic paraplegia. However, its role in human tumors remains poorly elucidated. Here, we comprehensively analyzed SELENOI expression patterns, functions, and clinical implications across various malignancies through the integration of bulk transcriptomics, cancer databases, and in vitro and in vivo experiments. Pan‐cancer analysis indicated upregulated SELENOI expression across various cancers, correlating with augmented malignancy, suppressed tumor immunity and poor prognosis. Knockdown of SELENOI caused G0/G1‐phase cell cycle arrest and diminished aggressive cancer phenotypes in OV cells. Moreover, SELENOI inhibition augments ferroptosis and reverses the cisplatin resistance in OV cells by modulating Akt phosphorylation. Conversely, overexpression of SELENOI in OV cells enhanced therapeutic sensitivity to cisplatin by upregulating Akt phosphorylation. Importantly, in vivo studies demonstrated that SELENOI inhibition suppressed ovarian tumor growth and enhanced cisplatin's anticancer effects. These findings highlight the significant role of SELENOI in OV by modulating ferroptosis and chemotherapy resistance. Targeting SELENOI represents a promising therapeutic approach to promote the efficacy of platinum‐based chemotherapy in OV, particularly in cases of resistance.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Gynecology Shenzhen Second People's Hospital the First Affiliated Hospital of Shenzhen University Shenzhen China.
- Guangdong Key Laboratory for Biomedical Measurements and Ultrasound Imaging National-Regional Key Technology Engineering Laboratory for Medical Ultrasound School of Biomedical Engineering Shenzhen University Medical Sch…
- Department of Endocrinology and Metabolism Nanfang Hospital Southern Medical University Guangzhou China.
- Shenzhen Key Laboratory of Reproductive Immunology for Peri-implantation Shenzhen Zhongshan Institute for Reproductive Medicine and Genetics Shenzhen Zhongshan Obstetrics & Gynecology Hospital Shenzhen China.
Förderung
- National Key Research and Development Program of China
- National Natural Science Foundation of China
Zitieren
APA
Li, J., Chen, M., Huang, D., Li, Z., Chen, Y., Huang, J., Chen, Y., Zhou, Z., & Yu, Z. (2024). Inhibition of Selenoprotein I promotes ferroptosis and reverses resistance to platinum chemotherapy by impairing Akt phosphorylation in ovarian cancer. MedComm, 5(12). https://doi.org/10.1002/mco2.70033
Vancouver
Li J, Chen M, Huang D, Li Z, Chen Y, Huang J, et al. Inhibition of Selenoprotein I promotes ferroptosis and reverses resistance to platinum chemotherapy by impairing Akt phosphorylation in ovarian cancer. MedComm. 2024;5(12). doi:10.1002/mco2.70033
BibTeX
@article{Li2024,
author = {Li, Jing and Chen, Mimi and Huang, Dingwen and Li, Ziyin and Chen, Yu and Huang, Jinhua and Chen, Yuanqun and Zhou, Zhili and Yu, Zhiying},
title = {Inhibition of Selenoprotein I promotes ferroptosis and reverses resistance to platinum chemotherapy by impairing Akt phosphorylation in ovarian cancer},
journal = {MedComm},
year = {2024},
volume = {5},
number = {12},
doi = {10.1002/mco2.70033}
}
EUVIMED